Meet Proteona at the 1st Advanced Therapies Science Meeting in Berlin, Germany
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Dr Andreas Schmidt, the CEO of Proteona Pte. Ltd., will attend the 1st Advanced Therapies Science Meeting (1ATSM), taking place in Berlin, Germany, from the 25th to the 26th November 2019.
The 1ATSM meeting is part of the RESTORE initiative in Europe. RESTORE aims to accelerate the development of advanced therapies, such as cell and gene therapy, and their translation into clinical standard-of-care. Proteona is a supporter of RESTORE.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.